“We are excited to welcome Eisai Inc. as the first biopharmaceutical company to this thriving center for health care,” Eugene Diaz, co-owner of Prism Capital Partners, a real estate owner and operator, said.
Eisai, which focuses on oncology and neurology, will transfer up to 1,200 corporate and research staff from Woodcliff Lake in late 2021 to 300,000 square feet at 200 Metro Blvd., the campus’ 15-story flagship LEED Gold certified office tower. The move will bring all of Eisai’s New Jersey-based employees together under one roof.
“Eisai is a human health care company. This ON3 Eisai workplace will bring the Eisai community together in one place and drive a culture of new scientific horizons and entrepreneurial innovation,” Tatsuyuki Yasuno, president of Eisai Inc., said. “We draw inspiration from our patients and passion from our people. We break barriers every day. Our workplace will too.”
Prism acquired the former Hoffman-La Roche site in 2016, representing New Jersey’s largest redevelopment project. The firm has also brought together a mix of pharmaceutical, research and development, medical education, and diagnostics to one singular life sciences campus.
“Eisai brings exceptional scientific and business expertise to this ever-expanding center for New Jersey and global business in a lease that has brought the campus to 100% occupancy,” Edwin Cohen, co-owner of Prism Capital Partners, said.